From CNBC: 2025-05-01 07:54:00

Eli Lilly reported strong first-quarter revenue and earnings, driven by high demand for its weight loss and diabetes drugs, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal. The pharmaceutical giant now expects adjusted fiscal 2025 earnings between $20.78 and $22.28 per share. The company also maintained its fiscal 2025 sales guidance of $58 billion to $61 billion.

Eli Lilly CEO Dave Ricks stated that the threat of tariffs is already bringing back critical supply chains into important industries like pharmaceuticals. He expressed the need for permanent lower tax rates in the U.S. to encourage domestic production. The company’s diabetes treatment, Mounjaro, and weight loss drug, Zepbound, surpassed expectations for the first quarter, with revenues of $3.84 billion and $2.31 billion, respectively.

Analysts expected Mounjaro and Zepbound to generate $3.81 billion and $2.28 billion in sales, respectively. Shares of Eli Lilly fell 5% in premarket trading. The company reported first-quarter earnings per share of $3.34 adjusted, higher than the expected $3.02, and revenue of $12.73 billion, beating the estimate of $12.67 billion.

Sales in the U.S. increased by 49% to $8.49 billion, driven by a 57% rise in volume for Zepbound and Mounjaro. Eli Lilly posted net income of $2.76 billion, or $3.06 per share, for the first quarter. Excluding one-time items, the company reported adjusted earnings of $3.34 per share. The popularity of Zepbound and Mounjaro has led to high demand, requiring investments to ramp up manufacturing capacity.



Read more at CNBC: Eli Lilly (LLY) earnings Q1 2025